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A 15-year-old male admitted for Pott’s puﬀy tumor developed recurrent episodes of fever, diﬀuse morbilliform rash, eosinophilia,
and tubulointerstitial nephritis while on multiple antibiotics. Lymphocyte blast transformation (LBT), a method of detecting cel-
lular immune response by measuring levels of interferon-γ (IFN-γ), was used to diagnose vancomycin hypersensitivity and guide
antibiotic selection.
1.Introduction
Drug allergies have a signiﬁcant impact on patient morbidity
and overall cost of the practice of medicine. Anywhere from
10–20% of hospitalized patients will have an adverse drug
reaction[1].Themostcommonclinicalpresentationofthese
reactions is cutaneous, such as urticaria and maculopapular
eruptions [2]. Adverse drug reactions from vancomycin
speciﬁcally can range from red man syndrome to leukocyto-
clastic vasculitis to anaphylaxis [3]. Less common reactions
include exfoliative dermatitis, linear IgA bullous dermatosis,
and delayed hypersensitivity reaction [4, 5].
Currently, diagnostic methods for suspected allergic re-
action to vancomycin are limited, and the diagnosis is often
made based by history alone. Skin puncture testing with
vancomycin results in frequent false positives secondary to
direct degranulation of mast cells [6]. Polk et al. performed
vancomycin skin testing on healthy volunteers and found
that all subjects tested had a positive reaction at concentra-
tions ≥10μg/mL [7].
We report a case of an adolescent patient who developed
a morbilliform rash while on multiple antibiotics. Lympho-
cyte blast transformation (LBT) was performed to involve
antibiotics to help determine the culprit. Although T-cell
Rx test (CD69 upregulation) for vancomycin delayed hyper-
sensitivity has become recently available [8], vancomycin
hypersensitivitydocumentedbyLBThasnotbeenpreviously
reported.
2.CaseReport
A 15-year-old male with a history of craniosynostosis and
developmental delay presented to the Emergency Depart-
ment with fever, headache, and swelling of the left forehead.
A CT scan revealed left frontal sinusitis with extension of
the inﬂammatory process through the left frontal bone into
the subperiosteal region (Pott’s puﬀyt u m o r )a n ds u b g a l e a l
region. The patient also had evidence of metallic sutures and
fenestrated plate to the superior margin of the left frontal
sinus consistent with his past medical history of repaired
craniosynostosisat6monthsofage.Familyhistoryandsocial
history were unremarkable for drug reactions. The patient
was started on vancomycin and ceftriaxone upon admission
and underwent bifrontal craniotomy, exoneration of frontal
sinuses with vascularized pericranial rotational graft, an en-
doscopic left-sided ethmoidectomy, and maxillary antros-
tomy. Gram stain of the purulent material obtained from the
surgery revealed Gram-positive cocci in pairs, chains, and
clusters while the culture grew rare anaerobic Gram-ne-
gative cocci, which we were unable to speciate. Given con-
cerns of polymicrobial infection with potential foreign body
involvement, his regimen was changed to vancomycin and2 Case Reports in Pediatrics
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Figure 1: Secreted fraction of INF-γ production by the patient’s
peripheral lymphocytes after 18h stimulation with various concen-
trations of Vancomycin and Metronidazole. The patient did not
produce any detectable levels of INF-γ with Ceftriaxone, Amox-
icillin, and Meropenem stimulation at all drug concentrations
(<0.16IU/mL). Likewise, the levels of INF-γ production in Vanco-
mycin-na¨ ıve control subject were below the threshold of detection
(<0.16IU/mL) at all Vancomycin concentrations.
meropenem. The patient defervesced, and his edema sub-
sided. On hospital day 8–10, he developed a diﬀuse, erythe-
matous morbilliform rash, fevers up to 40◦C, and elevated
b l o o dp r e s s u r e sw i t hs y s t o l i cm e a s u r e m e n t st o1 6 0m m H g .
Laboratory examination revealed new onset eosinophilia
(max. absolute eosinophil count 980/mm3), mild elevation
of creatinine and 1−2+ proteinuria, consistent with drug
associated hypersensitivity and tubulointerstitial nephri-
tis. Vancomycin and meropenem were discontinued and
changed to ceftriaxone and metronidazole on hospital day
10. The patient promptly defervesced with gradual improve-
ment of the rash, but on hospital day 14 developed low-
gradefevers(Tm 38.1◦C) and recurrence of diﬀuse rash. Skin
exam revealed widespread maculopapular erythematous
rash, prominent on the arms, legs, and trunk, especially
abdomen. No blisters or drainage were associated with the
rash and there was no mucosal involvement.
LBT was performed as described in the methods and
results section. Lymphocytes incubated with vancomycin
showed a robust response and those incubated with metron-
idazole showed an equivocal response (likely contributing to
the recurrence of rash on hospital day 14). The remainder
of the antibiotics tested did not show signiﬁcant IFN-γ
production. The patient tolerated a treatment regimen of
ceftriaxone and clindamycin with resolution of rash and
return to his baseline temperatures. He completed a total
course of 4-weeks of antibiotics without any signs of relapse.
3. Methods and Results
Lymphocyte blast transformation is a method for detection
of cellular immune response based upon the premise that
stimulated or sensitized lymphocytes will revert to blast for-
mation and produce detectable levels of IFN-γ, which are
directly proportional to the level of sensitization. Testing
was performed using the QuantiFERON-CMI testing kit
(Cellestis, Victoria, Australia, http://www.cellestis.com/)[ 9].
Heparinized whole blood was collected, and ex vivo LBT
was performed with phytohemagglutinin (PHA), pokeweed
mitogen (PWM), concanavalin A (Con A) to evaluate the
patient’s baseline immune function. The patient’s whole
blood was incubated with antibiotics at varying dilutions
designed to mimic actual serum concentration for 18 hours
at 37◦C in a 24-well tissue culture plate. Then using a pi-
pette, 200–300μL of plasma above the sedimented red cells
was transferred to a new well plate (anti-human IFN-γ
antibodies bound to the solid phase), and IFN-γ pro-
duction was then quantitatively measured using enzyme-
linked immunosorbent assay (ELISA) utilizing enzyme-la-
beled IFN-γ antibodies in solution. The interferoncutoﬀ was
set at 0.16IU/mL, which was determined by plotting the
optical density against a standard curve generated according
to the manufacture’s instructions.
In our patient, his response to PWM, PHA, and the kit’s
mitogen positive control was within the expected ranges.
The positive control included in the QuantiFERON-CMI
testing kit generally elicits the greatest IFN-γ response for
any given individual. The response to Con A was less than
expected at 0.269IU/mL (eﬀective response >0.6). There was
a remarkable concentration-dependant response to vanco-
mycin, an equivocal response to metronidazole, and no re-
sponse to ceftriaxone, amoxicillin, and meropenem; see
Figure 1. Vancomycin hypersensitivity was diagnosed.
4. Discussion
Maculopapular eruptions are a common manifestation of
nonimmediate allergic drug reactions and are mediated via
drug-speciﬁc T cells. Drugs are low-molecular-weight chem-
icals that can interact with T cells, speciﬁcally their receptors,
to activate an immune response. Once activated, the drug-
speciﬁc T cells migrate into the skin and cause inﬂammatory
damage with the release of various cytokines [10].
One of the original methods of determining cell stim-
ulation was via the lymphocyte transformation test, which
is an in vitro assay that measures the rate of 3H-thymidine
or bromodeoxyuridine uptake in replicating DNA [11]. Its
clinical use has been discussed in the literature for detection
of delayed hypersensitivity reactions to certain antibiotics,
antiepileptics, antihypertensives, NSAIDS, anesthetics, and
radiocontrast media [12]. LBT has the advantage over the
lymphocyte transformation test of a quicker turn-around
time (usually 24–48 hours) since there is no radioisotope or
need to culture cells. Recently, Beeler et al. reported on the
u s eo fC D 6 9u p r e g u l a t i o no nTc e l l sa sa na c t i v a t i o nm a r k e r
for delayed-type drug hypersensitivity [8]. In contrast, LBT
is a functional assay for detecting IFN-γ production by sen-
sitized T cells in response to speciﬁc antigen or mitogen
[9]. There is no previously published report on the use of
increased IFN-γ production to diagnose vancomycin hyper-
sensitivity.Case Reports in Pediatrics 3
The patient described in this paper demonstrates a com-
mon scenario encountered by consulting allergists and infec-
tious diseases specialists. Due to the lack of speciﬁcity and
sensitivity of skin testing for some medications, the patient
history is often relied upon to determine which antibiotic
is the causative agent in a drug reaction. Reliable diagnosis,
though diﬃcult, is necessary for safe and eﬀective patient
treatment. This patient had a complicated sinus infection
requiring long-term broad-spectrum coverage, which was
further complicated by recurrent episodes of fever and rash
resulting in the use of multiple classes of antibiotics. His
morbilliform rash was initially thought to be secondary to
c e p h a l o s p o r i n s .H o w e v e r ,w ew e r ea b l et od e t e r m i n et h a t
vancomycin and possibly metronidazole were likely to be
responsible for the patient’s fever and rash. In this case, LBT
testing guided us in establishing an alternative regimen of
ceftriaxone and clindamycin.
The marked INF-γ levels detected using the quanti-
FERON-CMI kit indicates the presence of a speciﬁc T-cell-
mediatedimmuneresponseagainstvancomycin,whichisthe
immunologic basis for delayed-type hypersensitivity. Van-
comycin concentrations used were within therapeutic levels
and combined with the patient’s clinical course indicate that
LBT was useful in the diagnosis of vancomycin hypersensi-
tivity in this patient. Since it is a cellular immune response,
unsensitized individuals should show zero production of
interferon. Clearly, larger studies are needed to determine its
utilityinvariousclinicalscenarios.Therewasamildresponse
to metronidazole, which correlates with the relatively milder
clinical manifestation observed during metronidazole ther-
apy and possible metronidazole hypersensitivity. The results
o fan e g a t i v er e s p o n s et oβ-lactam agents were interpreted
with caution, and clinical response was monitored.
A potential limitation of LBT would be non-discrimi-
natory IFN-γ production that may be seen in a scenario of
multidrug hypersensitivity induced by superantigens. How-
ever, even in such a case, negative results can still be helpful.
Resultsneedtobereproducedinalargersamplesize.Further
evaluation is also needed to see if it can be used for hyper-
sensitivity to other medications and if other cytokines may
be more sensitive or speciﬁc for drug-related delayed-type
hypersensitivity.
5. Conclusions
Lymphoblast transformation is a useful test in conﬁrming
the etiology of vancomycin-induced delayed hypersensitivity
reaction.
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